Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naive patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions.

ABSTRACT:

Objective

To develop and externally validate a novel nomogram in biopsy-naïve patients with prostate-specific antigen (PSA) <10 ng/ml and PI-RADS v2.1 = 3 lesions.

Methods

We retrospectively collected 307 men that underwent initial biopsy from October 2015 to January 2022 in Cohort 1 (The First Affiliated Hospital of Soochow University). External cohort (Cohort 2, Kunshan Hospital) included 109 men that met our criteria from July 2016 to June 2021. By Slicer-3D Software, the volume of all lesions was divided into two subgroups (PI-RADS v2.1 = 3a and 3b). Logistic regression analysis was performed to screen for variables and construct nomogram by analyzing clinical data from Cohort 1. Receiver operating characteristics curve analysis, calibration plot and decision curve analy

SUBMITTER: Hu C 

PROVIDER: S-EPMC9939143 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature